Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ono, BMS File Opdivo/Yervoy Combo for MSI-H Colorectal Cancer in Japan
November 13, 2019
- Sandoz to Buy Aspen’s Japan Biz for Up to 400 Million Euros
November 12, 2019
- Mitsubishi Tanabe’s HIF-PH Inhibitor Shows Non-Inferiority to ESA in Japan PIII Study
November 12, 2019
- Japan Ethical Drug Sales Spike 19.7% in September: Crecon
November 12, 2019
- Satralizumab Submitted in Japan for NMOSD
November 11, 2019
- Esaxerenone Hits Primary Goal in Japan PIII Study for Diabetic Nephropathy: Daiichi Sankyo
November 11, 2019
- Ninlaro Meets Primary Endpoint as 1st-Line Maintenance Therapy for Multiple Myeloma: Takeda
November 11, 2019
- Nippon Kayaku Forecasts 4.3 Billion Yen Full-Year Sales for Biosimilars
November 11, 2019
- BI Japan and Nippon BI to Merge in January Next Year to Increase Management Efficiency
November 11, 2019
- China Emerges as a Key Destination for New Clinical Trials in 2018: Informa Report
November 8, 2019
- Japan Market Logs Hefty 8.9% Growth in July-September: IQVIA
November 8, 2019
- AstraZeneca’s COPD Triplet Promotion Stands Out in August: Impact Track
November 8, 2019
- Keytruda Stays on Top in October Japan Drug Ranking: Encise
November 8, 2019
- Takeda’s Dengue Vaccine Candidate Showed Confirmed Protection Efficacy in PIII
November 8, 2019
- As Trintellix Debut Nears, Lundbeck Japan Morphing into Full-Fledged Commercial Company
November 7, 2019
- 3rd Conditional Approval Candidate Was DMD Drug Viltolarsen, Nippon Shinyaku Reveals
November 7, 2019
- Takeda Acquires Rights to CAR NK Cell Therapies from MD Anderson
November 7, 2019
- Takeda Opens New Dengue Vaccine Manufacturing Facility in Germany
November 7, 2019
- 8 Japan Majors Log Combined Sales Rise in 1st Half on Shire Buy, Solid Earnings at Home
November 6, 2019
- Fairly Good If Gilenya Royalty Issue Could Be Settled in 2 Years: Mitsubishi Chemical CFO
November 6, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…